<p>Spevigo is a medicine that acts on the immune system. It is used in adults and adolescents from 12 years of age to prevent and treat flare-ups (recurrence or worsening) of generalised pustular psoriasis, an inflammatory skin disease causing pustules (pus-filled lesions) to appear over large areas of skin.</p><p>Spevigo contains the active substance spesolimab.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Spevigo is indicated for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age.</p><p>Spevigo is indicated for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy.</p></div>
Therapeutic Area (MeSH)
ATC Code
L04AC22
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| spesolimab | N/A | spesolimab |
EMA Name
Spevigo
Medicine Name
Spevigo
Aliases
N/ANo risk management plan link.
